Form 4: Allarity Therapeutics CDO, Jeremy R. Graff, Acquires Shares Through Restricted Stock Units

Allarity Therapeutics' Chief Development Officer, Jeremy R. Graff, acquired 144,441 shares of common stock through the vesting of restricted stock units.

Summary

• Jeremy R. Graff, the Chief Development Officer of Allarity Therapeutics, Inc., acquired 144,441 shares of common stock on January 22, 2025.
• These shares were acquired through the vesting of restricted stock units (RSUs) granted under the company's 2021 Equity Incentive Plan.
• The RSUs will vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent on Mr. Graff's continued employment with the company.
• Following this transaction, Mr. Graff directly owns 262,924 shares of Allarity Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The vesting of RSUs aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the CDO.

Future Outlook

The remaining RSUs will vest over the next two years, subject to Mr. Graff's continued employment.

Industry Context

This is a standard practice for incentivizing and retaining key executives in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Equity-based compensation, such as RSUs, is a common practice among publicly traded companies, especially in the biotechnology sector, to align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity incentive plans for their executives.
• The vesting schedule of one-third annually is a typical approach to ensure long-term commitment from key personnel.

Stakeholder Impact

• Shareholders may view this positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Allarity Therapeutics, Jeremy R. Graff, restricted stock units, RSUs, equity incentive plan, share acquisition, insider trading, beneficial ownership